Optimized Workflow for Structure Elucidation of Pharmaceutically Relevant Extractables and Leachables

Significance of E&L Analysis

Extractables and leachables (E&L) screening is critical in pharmaceutical quality control to ensure that materials in contact with drug products do not introduce harmful impurities. Robust structural elucidation methods reduce risk, improve patient safety, and support regulatory compliance.

Objectives and Overview of the Study

This work presents an optimized workflow for the comprehensive characterization of small-molecule extractables and leachables using a Thermo Scientific Orbitrap ID-X Tribrid mass spectrometer with the AcquireX acquisition strategy. Key goals were to maximize MSn coverage, improve precursor selection efficiency, and streamline data processing to accelerate E&L identification in complex drug and packaging matrices.

Methodology and Instrumentation

Sample Preparation

• An additive standard mixture at 10 ppm in 50 / 50 IPA/H₂O diluted with drug excipients to 1 ppm.
• Extracts from three types of medical-grade O-rings obtained by 7 day extractions at 50 °C in pH 3, pH 9, and IPA solvents.

Liquid Chromatography

• Vanquish Flex UHPLC with Hypersil GOLD C18 column (100 × 2.1 mm, 1.9 µm).
• 45 °C column temperature, 400 µL/min flow, 5 µL injection.
• Gradient: 5 % B to 95 % B over 15 min (A = H₂O / 0.1 % FA; B = ACN / 0.1 % FA).

Mass Spectrometry

• Orbitrap ID-X Tribrid MS with electrospray ionization in positive mode.
• AcquireX dynamic background exclusion and inclusion workflows: background exclusion, combined exclusion/inclusion, and deep scan.
• Full-scan MS at 120 000 resolving power; HCD MS2 and CID MS3 at 30 000 and 15 000.

Data Processing

• Thermo Scientific Compound Discoverer 3.0 for feature detection and annotation.
• Thermo Scientific Mass Frontier 8.0 for structure elucidation and library generation.

Main Results and Discussion

Compared with conventional data-dependent acquisition (DDA), AcquireX strategies doubled the number of MSn events on target compounds. In the spiked additive study, traditional DDA triggered MSn for three additives, whereas AcquireX background exclusion enabled fragmentation of six additives. Complex O-ring extracts yielded detection of multiple sulfur-containing leachables that were otherwise masked by solvent background. Chromatograms from samples A, B, and C demonstrated increased peak coverage and intensity for low-abundance species.

Benefits and Practical Applications

The optimized workflow delivers

• Enhanced sensitivity for trace E&L compounds.
• Greater depth of MSn fragmentation for confident structure assignment.
• Faster cycle times by automatic background exclusion.
• Streamlined data analysis from acquisition to reporting.

This approach supports pharmaceutical impurity profiling, metabolite identification, degradant analysis, and broader small-molecule characterization tasks.

Future Trends and Opportunities

Advances may include integration of real-time data processing, machine learning for automated compound annotation, and expansion to negative-ion workflows. Such developments will further increase throughput and confidence in E&L screening and other small-molecule structural studies.

Conclusion

The combined Orbitrap ID-X MS with AcquireX acquisition and dedicated data-processing tools provides a robust, high-efficiency workflow for pharmaceutical E&L structure elucidation. This strategy enhances detection of critical extractables and leachables, streamlines analysis, and can be adapted to diverse small-molecule applications.

References

No specific literature citations were provided in the source document.